FDA OKs Cardiovascular Surgical Patch

WASHINGTON, April 5 (UPI) — The U.S. Food and Drug Administration announced approval Monday of the first absorbable fibrin sealant patch for use during cardiovascular surgery.

The FDA said the TachoSIl blood-clotting patch, which is eventually absorbed by the body, is used to prevent mild and moderate bleeding from small blood vessels when other standard surgical techniques are ineffective or impractical.

“TachoSil is a ready-to-use surgical patch composed of a dry collagen sponge made from horse tendons, and coated with fibrinogen and thrombin,” the FDA said in a statement. “At the site of a wound, the two proteins, through a series of chemical reactions, produce fibrin, a stringy, white, insoluble protein that allows a clot to form.”

The patch is biodegradable and breaks down inside the body within four to six months.

TachoSil is manufactured by Nycomed Austria GmbH of Linz, Austria.

Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.

Categorized | Other
Leave a Reply

You must be logged in to post a comment.